Cancer treatments induce cell stress to trigger apoptosis in tumor cells. Many cancers repress these apoptotic signals through alterations in the Bcl2 proteins that regulate this process. Therapeutics that target these specific survival biases are in development, and drugs that inhibit Bcl2 activities have shown clinical activity for some cancers. Mcl1 is a survival factor for which no effective antagonists have been developed, so it remains a principal mediator of therapy resistance, including to Bcl2 inhibitors. We used a synthetic-lethal screening strategy to identify genes that regulate Mcl1 survival activity using the pediatric tumor neuroblastoma (NB) as a model, as a large subset are functionally verified to be Mcl1 dependent and Bcl2 inhibitor resistant. A targeted siRNA screen identified genes whose knockdown restores sensitivity of Mcl1-dependent NBs to ABT-737, a small molecule inhibitor of Bcl2, BclXL and BclW. Three target genes that shifted the ABT-737 IC50 41 log were identified and validated: PSMD14, UBL5 and PRPF8. The latter two are members of a recently characterized subcomplex of the spliceosome that along with SART1 is responsible for non-canonical 5 0 -splice sequence recognition in yeast. We showed that SART1 knockdown similarly sensitized Mcl1-dependent NB to ABT-737 and that triple knockdown of UBL5/PRPF8/SART1 phenocopied direct MCL1 knockdown, whereas having no effect on Bcl2-dependent NBs. Both genetic spliceosome knockdown or treatment with SF3b-interacting spliceosome inhibitors like spliceostatin A led to preferential pro-apoptotic Mcl1-S splicing and reduced translation and abundance of Mcl1 protein. In contrast, BN82865, which inhibits the second transesterification step in terminal spliceosome processing, did not have this effect. These findings demonstrate a prominent role for the spliceosome in mediating Mcl1 activity and suggest that drugs that target either the specific UBL5/PRPF8/SART1 subcomplex or SF3b functions may have a role as cancer therapeutics by attenuating the Mcl1 survival bias present in numerous cancers.
1
These proteins interact with Bcl2 family members at the outer mitochondrial membrane, where a subset, including Bid and Bim, can directly activate the obligate executioners Bak or Bax to commit the cell to death. Alternatively, activated BH3-only proteins may be sequestered within the hydrophobic pocket of the pro-survival proteins Mcl1, Bcl2, BclxL, Bclw or A1/Bfl, neutralizing their death signals.
2 Neuroblastoma (NB) is a highly lethal childhood tumor that we have previously shown to be dependent on pro-survival Bcl2 family proteins to neutralize activated Bim and evade apoptosis. 3, 4 They can be functionally classified into three categories: those dependent on Bcl2 for survival, those dependent on Mcl1, and post-therapy relapsed tumors with profound mitochondrial-apoptosis resistance. The small molecule ABT-737, an inhibitor of Bcl2, BclxL and Bclw, has low nanomolar potency against Bcl2-dependent cell lines and in vivo efficacy in pre-clinical models. 3, 4 However, this agent does not antagonize Mcl1, 5 which remains an important resistance mediator for Mcl1-dependent NBs and many other tumor histotypes. For this reason, there remains great interest in developing Mcl1 antagonists for clinical use.
Knocking down Mcl1 in Mcl1-dependent cancer cells restores sensitivity to ABT-737 confirming it as a principal survival factor, 6 so we sought to use the specific activity of ABT-737 in a synthetic-lethal siRNA screen to identify targets that support Mcl1 activity. Mcl1 is unique among Bcl2 prosurvival family members in its short half-life (1.5-6 h) and myriad regulatory influences altering stability and function.
can generate multiple isoforms. 8, 9 Mcl1 is further regulated post-translationally, with constitutive turnover occurring via ubiquitin-mediated degradation through the Huwe1 Hect E3-ligase. 10 The E3-ligase, BTRC, operating downstream of AKT and GSK3b, 11 and Fbw7, the substrate recognition subunit of the SCF complex, also function to degrade Mcl1. 12 Conversely, deubiquitinases (DUBs) that selectively remove ubiquitin from substrates to promote their stability have been implicated in stabilizing oncoproteins, such as Mcl1. 13 Usp9x has been proposed as a specific Mcl1 DUB in lymphomas and multiple myeloma, and interfering with its activity restores sensitivity to ABT-737, 14 though no such correlation has been identified in NB.
Given the extensive regulation of Mcl1 by the ubiquitinproteosome system, we hypothesized that a specific DUB sustained Mcl1 activity in NB. We therefore chose an siRNA library targeting DUBs for our screen and identified gene targets that sensitize cells to ABT-737. Unexpectedly, we validated that the proteosomal lid component, PSMD14, and multiple components of the splicosome (PRPF8, UBL5, and SART1) promote Mcl1 pro-survival activity. The latter were included in the library as they contain DUB or ubiquitin-like motifs, although their Mcl1 effects are independent of canonical DUB activities. Inactivating these components by RNAi or biochemical inhibition causes pro-apoptotic splicing changes in Mcl1, reduced Mcl1 translation and restored sensitivity of Mcl1-dependent NBs to ABT-737. Collectively, these data identify targets for restoration of apoptotic signaling in Mcl1-dependent cancers by exploiting its highly regulated nature, specifically in antagonizing spliceosomemediated events.
Results
An siRNA screen identifies PRPF8, UBL5 and PSMD14 as targets that are synthetic-lethal with Bcl2 antagonists in Mcl1-dependent cancers. We used an siRNA library to target 98 DUBs in two cell lines dependent on Mcl1 for survival: IMR5 and NLF. 3 Though both express Bcl2 protein, they neutralize Bim exclusively through Bim:Mcl1 binding and are resistant to the Bcl2 antagonist ABT-737 in vitro and in vivo. 3, 4 Direct knockdown of Mcl1 sensitizes these cells to ABT-737 (IC50 2 and 30 nM, respectively), 4100-fold less than their IC50 to ABT-737 without Mcl1 knockdown. We screened in the presence of 200 nM ABT-737 as this concentration was 410-fold less than the IC50 in parental cells and B10-fold greater than the IC50 following Mcl1 knockdown, demonstrating maximally divergent cytotoxicity ( Figure 1a ). Using a Z-score of o À 1.5 in cells co-treated with ABT-737 and siRNA and a ratio of (ATP-ABT737/ATPvehicle) o0.80 to define our hit threshold, PSMD14, PRPF8, UBL5 and UCHL3 were identified as Mcl1 activators in IMR5 and PSMD14, PRPF8, and USP17 in NLF (Figures 1b and c  and Supplementary Table S1 ). USP9X had Z-scores of 0.40 in IMR5 and À 0.10 in NLF, and Usp9x protein levels did not correlate with Mcl1 protein or activity. Indeed, Usp9x activity had not been identified in neural tissues or NB cell lines, in contrast with hematolymphoid tissues. NLF  IMR5  IMR5 siSham  IMR5 siMCL1  NLF siSham  NLF siMCL1  SMS-SAN siSham   siPSMD14  siPRPF8  siUBL5  siMCL1  siSham   siPSMD14  siPRPF8  siUBL5  siMCL1  siSham   siPSMD14  siPRPF8  siUBL5  siMCL1  siSham   PSMD14  PRPF8  UBL5   NLF   UCHL3 siRNA Alone % Change with ABT-737 PSMD14 PRPF8
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Figure 1 We verified screen results with siRNA knockdown of each target gene markedly reducing the IC50 to ABT-737 except for USP17, which was not studied further (Figures 1d-f and  Table 1 ). We next measured the ABT-737 IC50 with each individual siRNA from the pool targeting each gene, and multiple siRNA constructs targeting PRPF8, PSMD14 and UBL5 each demonstrated a 410-fold reduction in ABT-737 IC50 supporting on-gene effects (Table 1) . Only one UCHL3-targeted siRNA construct shifted the IC50 so UCHL3 was not studied further. We measured the ABT-737 IC50 across NB cell lines verified as Bcl2 dependent (SMS-SAN) or therapy resistant (SK-N-AS and BE2C, established at the time of relapse). 3 The notable reduction in ABT-737 IC50 was confined to tumor cells functionally dependent on Mcl1 (with the exception that PSMD14 knockdown decreased the IC50 to ABT-737 in therapy-resistant BE2C cells; 3, 4 Table 1 ). Thus, UBL5, PRPF8 and PSMD14 were validated hits, with PSMD14 and PRPF8 confirmed in both cell lines.
To further validate on-target activities, we performed rescue experiments expressing each gene with a translationally silent mutation rendering it siRNA resistant. Expressing knockdown-resistant pUBL5 (Po0.01) or pPSMD14 (Po0.01) rescued cells from siRNA-mediated ABT-737 sensitization, compared with LacZ control transfection ( Figure 2 ). We were unable to stably express pPRPF8, so rescue of its knockdown phenotype could not be tested. As we initially sought a DUB activity that sustained Mcl1, we assessed whether these genes functioned through ubiquitin-mediated mechanisms. We engineered an siRNA-resistant PSMD14 mutating two critical JAMM motif residues, H113A and H115A (pPSMD14-H4A), that failed to rescue the phenotype of PSMD14 knockdown, supporting that its protease activity is required to promote Mcl1 function (Figure 2c ). In contrast, UBL5 is a ubiquitin-like modifier that lacks the C-terminus diglycine (GG) by which ubiquitin is bound to its substrates. Instead, it has a dityrosine before a terminal non-conserved residue. 16 Similar ubiquitin-like modifications have been implicated in regulating Bcl2 family proteins, 17 but an siRNA-resistant UBL5 that lacked the terminal YYQ residues (pUBL5-Cterm) did rescue cells from siRNA knockdown (P ¼ 0.03) similar to wild-type UBL5, indicating that C-terminal conjugation to substrates is unlikely to be its primary mechanism for Mcl1 antagonism (Figure 2 ).
Spliceosome complex components are potential regulators of Mcl1. The Saccharomyces cerevisiae homolog of UBL5, Hub1, functions within a spliceosome complex with Snu66 and Prp8 (the yeast homolog of PRPF8), binding via a novel HIND interaction domain independent of the terminal dityrosine. 15 This complex does not effect global spliceosome activities in yeast but is required for alternative (in distinction to canonical) 5 0 -splice site usage. 18 As two of Figure S1A ). Simultaneous knockdown of UBL5, PRPF8 and SART1 nearly phenocopied direct Mcl1 knockdown, whereas this triple knockdown had no effect in SMS-SAN cells that are Bcl2 dependent (Supplementary Figure S1B) . These data support a novel role for this spliceosome complex in mediating Mcl1 activity. Mcl1 protein expression was reduced by knockdown of UBL5, SART1 or PRPF8 in Mcl1-dependent cells (in contrast to PSMD14 knockdown that led to Mcl1 accumulation, Figure 3a ). Given a postulated role for the spliceosome in this process, we assessed Mcl1 mRNA splicing. MCL1-L is the ubiquitous pro-survival isoform, MCL1-S is generated by exon skipping and contains a BH3 death domain and MCL1-ES has a novel intron in the first exon of MCL1-L but is not expressed in NB. 8, 9 Despite MCL1-L protein reduction with spliceosome component knockdown, MCL1-L mRNA was not consistently reduced, suggesting transcriptional repression is not a major effector (Figure 3b ). Knockdown of spliceosome complex members increased MCL1-S abundance and the MCL1-S/MCL1-L ratio as confirmed by both RT-PCR and QPCR (Figures 3c and d) , and as Mcl1-S is reported to be proapoptotic, we tested whether this level of MCL1-S expression phenocopies spliceosome knockdown. First, we expressed Mcl1-S using a tetracycline-inducible construct, and there was a trend to an inverse correlation between ABT-737 sensitivity (IC50) and MCL1-S abundance across subclones (r ¼ À 0.78, Po0.07; Figure 4 ), yet even those expressing MCL1-S comparable to spliceosome-component knockdown (see Figures 3c and 4d) did not fully restore ABT-737 sensitivity (IC50 reduced only to 1.4 mM). We also used morpholino oligonucleotides to induce exon skipping and promote Mcl1-S splicing. 19 Again a dose-response effect was seen (more notable in IMR5) that again led to only modest reductions in ABT-737 IC50 (41 mM; Figure 4 ). Therefore, genetic knockdown of UBL5/PRPF8/SART1 increased Mcl1-S, but our data suggest that this is not the principal effector for Mcl1 antagonism but that reduced Mcl1-L protein is the major contributor.
In addition to Mcl1 itself, regulators of Mcl1 might be alternatively spliced to alter Mcl1 activity, so we assessed splicing in a panel of such genes in response to spliceosome knockdown: BCL2L1 (Bclx), BCL2L11 (Bim), BAX, MAPK8 (Jnk), EPHB2 (Erk), GSK3B, HUWE1, BTRC, USP9X, EIF4E, AKT1, and STAT3. Similar to Mcl1, the predominant change was an increase in exon skipping (for BAX, GSK3B, HUWE1 and BTRC), while there was increased alternate splice donor site usage for BCL2L1 to generate Bclx-S preferentially over Bclx-L (Figure 5a ). The remaining genes had no splice alterations identified. Notably, no non-canonical 5 0 -splice donor site splice alterations, as regulated by Hub1/Prp8/ Snu66 activities in yeast, were seen. Overall, splicing changes were most pronounced with BTRC, reducing the full-length isoform while increasing exon 2 skipped product, and generating novel exon 2-3 and exon 2-4 skipped products. None of these alternatively spliced products (that generate in frame deletions that skip amino acids 17-52, 17-78 and 17-108, respectively) have been reported to antagonize Mcl1, 20 so their effect on Mcl1 regulation is unclear. We were unable to forcibly overexpress these splice-altered BTRC isoforms at the protein level to directly assess their impact on Mcl1 stability or activity. To indirectly assess whether BTRC or an unidentified regulator decreased Mcl1 translation, without reducing transcription or protein stability. As splicing is required for the efficient transport of mRNA to the cytosol for translation, it is possible that altered spliceosome activities lead to reduced Mcl1-L protein through inhibited mRNA trafficking and translation. 21 Small molecule spliceosome complex inhibitors phenocopy Mcl1 antagonism. Ubl5, Prpf8 and Sart1 copurify with the U5-U4/U6 tri-snRNP complex of the spliceosome that is recruited to join U1 and U2 snRNP complexes that recognize splice donor and acceptor sites. [22] [23] [24] Whether Ubl5/Prpf8/Sart1 have restricted roles or provide target selectivity within the spliceosome is unknown, and no inhibitors of this subcomplex have been identified. However, inhibitors of SF3b, a component that directly interacts with Prpf8 25 and inhibits the immediate upsteam U2 snRNP complex, have been developed. 26 Knockdown of SF3B1, the SF3B member most highly expressed in NBs, sensitized Mcl1-dependent IMR5 and NLF cells to ABT-737 (IC50 of 64 and 276 nM, respectively) and markedly skewed Mcl1 splicing toward the pro-apoptotic Mcl1-S isoform, analogous to Ubl5, Prpf8 and Sart1 knockdown (Figures 6a-c) . Biochemical inhibition of SF3b by spliceostatin A (SSA), a methylated derivative of FR901464, 26 resulted in nearabolished Mcl1-L expression and, importantly, phenocopied direct Mcl1 knockdown with respect to ABT-737 sensitization (IC50 to ABT-737 of 6.8 and 28.5 nM in IMR5 and NLF, respectively; Figures 6d and e). SSA-mediated resensitization to ABT-737 was seen not only in the Mcl1-dependent subset but also in therapy-resistant cells (with repressed mitochondrial signaling) that utilize Mcl1 to sequester activated Bim, 4 as SSA increased sensitivity to ABT-737 in BE2C cells (IC50 13 nM) and, to a lesser degree, in SK-NAS cells (Figures 6i and j) . This suggests that spliceosome antagonists may have utility in the relapsed setting for chemoresistant tumors that depend on Mcl1. To see whether there was specificity within the spliceosome for this activity, we investigated BN82865, a napthoquinone that blocks the second transesterification step acted upon complex C*, a late step in spliceosome processing. 27 Unlike SSA and other U2 antagonists like Meayamycin B, BN82865 did not alter Mcl1 activity or ABT-737 sensitivity in Mcl1-dependent cells (Supplementary Figure S2) , despite inhibiting the spliceosome complex that still included Ubl5, Prp8 and Sart1 supporting that earlier spliceosome inhibition correlated with Mcl1 antagonism. 27 SSA induced a near-complete shift from Mcl1-L to Mcl1-S isoforms, yet although Mcl1-S mRNA exceeded those seen with spliceosome knockdown, this was not reflected in significantly increased Mcl1-S protein (Figures 3 and 6f) . Figure S4) . The lack of sensitization to ABT-737 in these cells supports that functional studies rather than Mcl1 protein expression alone are required to define cells with Mcl1 dependence.
Expression of splicing components correlates with poor outcome NB. Mcl1 activity provides a survival bias in cancer and has been associated with therapy resistance in NB. 6 We therefore correlated the expression of spliceosome subcomplex genes with prognostic variables and clinical outcome in NBs (r2.amc.nl; 28 ). Using an expression data set of 649 NBs with associated prognostic information, the poor prognosis variables of age 418 months at diagnosis, stage 4 disease and MYCN amplification were all highly associated with high expression of SART1, UBL5, PRPF8 and SF3B1 at Po0.001, except for PRPF8 and MYCN amplification (P ¼ 0.11; Supplementary Figure S5 ). An independent set of 88 NBs in which survival outcome was also known showed an association between high SART1 and PRPF8 with inferior event-free survival (EFS) and overall survival and with SF3B1 with EFS alone (Supplementary Figure S5) . These correlations are consistent with a role for this spliceosome subcomplex in promoting Mcl1 activity, and survival bias, in NB. There was no correlation between Mcl1 mRNA expression and expression of any of these spliceosome components, consistent with our data that these are working through a post-translational mechanism and not directly on Mcl1 transcription.
Discussion
Apoptosis suppression is one of the hallmarks of cancer. 29 Alterations in Bcl2 family proteins commonly mediate this, so numerous agents that target Bcl2 family activities are in clinical development. 30 This includes the ABT-737 homolog, Navitoclax (Abbvie), a Bcl2, BclxL and BclW inhibitor with demonstrated activity in chronic lymphocytic leukemia 31 that is being studied in numerous clinical trials (clinicaltrials.gov). Navitoclax does not antagonize Mcl1, however, and this protein remains a major contributor to de novo and acquired resistance. 32 Therefore, there is great interest in identifying antagonists of Mcl1's pro-survival activity to potentially revert therapy resistance in Mcl1-dependent cancers or to synergize with Bcl2 antagonists by preventing emergence of Mcl1-mediated resistance.
Cancer cell dependence on specific Bcl2 homologs is defined functionally, as redundancy and extensive post-translational regulation make predictions from their expression levels alone difficult. For many tumors, their selective survival dependence reflects tonic Bim sequestration by specific Bcl2 pro-survival proteins. 4, 33 Many NBs are Mcl1 dependent and resistant to Bcl2 antagonists, demonstrating Bim sequestration by Mcl1. 4, 6 Knockdown of Mcl1 restores sensitivity to chemotherapy and to ABT-737 in this subset both in vitro and in vivo. 4 We exploited this dominant survival bias, and the highly regulated nature of Mcl1, using a focused siRNA synthetic-lethal screen that was highly specific, with all targets with a Z-score o À 2 validated as having effects on Mcl1 expression and activity. Our screen focused on DUBs to identify a DUB that rescues Mcl1 from proteosomal degradation in NB, analagous to USP9X in lymphoma. 14 We identified no such enzyme; however, it is possible that not all genes in our screen achieved adequate knockdown, particularly for proteins with a longer half-life, or that redundant DUB proteins promote Mcl1 activity in neural cells. We identified PSMD14, a component of the 19S proteasomal lid that has DUB activity, as a validated target whose knockdown leads to stabilization of Mcl1-L protein and paradoxical sensitization to ABT-737. Two additional 19S proteasome lid proteins have attributed DUB activity, Uchl5 and Usp14, 34 yet neither were hits in our screen, suggesting that there may be selectivity in substrate selection within this complex (Supplementary Table S1 ). Further work in this area is warranted as more selective proteasome inhibitors are now under development, including those that target 19S DUB activities, 34 and a less toxic Mcl1-specific inhibitor may be achievable.
Two validated targets, PRPF8 and UBL5, are components of the spliceosome and we focused on them as potential novel Mcl1 regulators, especially as Mcl1 has both pro-and antiapoptotic isoforms making this is an attractive mode of control. 8, 9 In yeast, loss of the UBL5 homolog Hub1 results in defective splicing at non-canonical 5 0 splice donor sites. The regulation of alternative splicing is substantially more complex in humans; however, Ubl5 and Sart1 physically interact 25 and co-localize in nuclear speckles 18 in human cells and associate with Cajal bodies, the nuclear subdomains where splicesome components are assembled. 35 This suggests that the subcomplex may serve similar activities. Our data that knockdown of UBL5 or SART1, the homolog of its yeast binding partner snu66, both induce alternative splicing confined to exon skipping and alternative donor site usage supports this conservation. Still, transcriptome-wide approaches will be important to broadly characterize the specific splicing alterations mediated by these proteins across diverse normal and malignant tissues.
Interestingly, Mcl1 survival activity antagonism was limited to perturbations predicted to impair spliceosome assembly and was not seen with an inhibitor of the downstream second transesterification reaction. Sf3b proteins are components of the U2 complex that initially assembles on pre-mRNA to form complex A. Prpf8 is a core component of the U5 complex that associates with the U4/U6 complex (including Sart1 and thus likely Ubl5) and joins complex A on pre-mRNA to form complex B during splicing (Figure 7) . 36 Roybal and Jurica 37 reported that SSA slows the transition from complex A to complex B with accumulation of an A-like complex with SSA treatment of nuclear extracts. Further, this complex formation was dependent on the 5 0 -splice donor site and branch point, but not the 3 0 acceptor site. We hypothesize that knockdown of components of complex B (PRPF8, UBL5 and SART1) may similarly slow this transition and explain the similar phenotype. Members of both complexes A and B were previously identified as Mcl1 splice regulators using an Mcl1-splice reporter construct in HeLa cells, in a targeted screen of genes that regulate BclXL splicing. 38 PRPF8 was a hit, but neither UBL5 nor SART1 were tested. The SR proteins SRSF1 and SRSF3 that regulate early spliceosome formation and splice site recognition were implicated in Mcl1 splicing in that study (as has been SRSF5 39 ). As with our findings, genetic knockdown of these genes led to a marked decrease in Mcl1-L protein but no change in protein stability or Mcl1-L mRNA (and variable increases in Mcl1-S mRNA) supporting an impact on Mcl1 translation. 39 The mechanisms for this in NB require further studies but may include reduced recruitment of mTORC1 to the pre-mRNA, which has been linked to decreased translation. 40, 41 Our work identifies spliceosome inhibition as a potential therapeutic target to antagonize Mcl1 in NB. Alternative splicing may similarly regulate Bcl2 family proteins in diverse tissues, 42, 43 as supported by our finding that SSA induces Mcl1-S splicing in carcinoma cell lines of diverse origin. However, alternative splicing shows tissue specificity and is particularly important in neural development, with many neuronal-restricted splice isoforms identified, 44, 45 so the mechanisms here could be restricted to neural tumors. Indeed, zebrafish expressing a hypomorphic SF3B1 46 gene or truncated PRPF8
47 demonstrate selective defects in neural crest development and neuronal apoptosis, respectively, while constitutional PRPF8-inactivating mutations in humans are causative of retinitis pigmentosa, a disease of the neural crest-derived retina. 48 However, a genome-scale siRNA knockdown screen using multiple myeloma, a hematolymphoid tumor with an Mcl1 survival dependence, 49 also identified three splicing components (PRPF8, SF3A1 and SNRPA1) as demonstrating selective lethality, and spliceosome components were the only hits with higher activity than Mcl1 knockdown itself. 50 In this study, seven proteasome targets were also identified (though not PSMD14) supporting that, while the specific regulatory proteins identified may differ across cancer types, the core regulatory pathways may be conserved in Mcl1-dependent cancers.
There is much interest in spliceosome inhibitors as anticancer therapeutics, 51 both because spliceosome components (including PRPF8 and SF3B1) have been identified as driver genes in hematological cancers 52 and because cancer cells may have a unique dependence on spliceosome activities. 53, 54 Spliceosome inhibitors, including natural products such as FR901464 and pladienolides, and synthetic analogs, such as SSA and meayamycin B, have potent anticancer activities but the basis for their therapeutic index remains unclear. 55, 56 Recently, meayamycin B was shown to alter Mcl1 splicing and restore sensitivity to ABT-737 in non-small cell lung cancer cells, although this occurred via reduced Mcl1-L mRNA. 57 We propose that one mechanism of selectivity is by decreasing the expression and function of Mcl1-L, allowing the activated BH3-only pro-death proteins expressed in tumor cells to induce apoptosis while sparing normal tissues, which are not primed for death by tonically activated BH3-only proteins. In future work, it will be important to identify whether the effect of spliceosome inhibitors on Mcl1 can be achieved with selective inhibition of splicing activities, as suggested by our finding that the Ubl5 and Sart1 are integral to this activity or requires more global splicing disruption.
Materials and Methods
Cell lines. NB cell lines previously shown to be Mcl1 dependent (IMR5, 58 NLF), Bcl2 dependent (SMS-SAN, NB-1643 59 ) and resistant (SK-N-AS, BE2C) were used. Cells were grown in RPMI-1640 (Life Technologies, Grand Island, NY, USA) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml of penicillin and 100 mcg/ml streptomycin. Tissue culture was at 37 1C in a humidified atmosphere of 5% CO 2 . All cell lines were confirmed as unique using STR-based genotyping (AmpFISTR, Life Technologies) and identity-confirmed using the COG cell line genotype database (www.cogcell.org). All cell lines routinely tested negative for mycoplasma contamination.
Optimization of transfection conditions. Transfection conditions were optimized for each cell line to achieve 470% knockdown for reporter genes (PPIB and GAPDH) with 480% viability using the Dharmacon (Pittsburgh, PA, USA) RTF Optimization Protocol 1. Dharmacon Cell Culture Reagent was used to dilute DharmaFect 1-4 transfection reagents with three-fold serial dilutions to concentrations ranging from 0.025 to 2.025 ml of Dharmafect per 25 ml of final suspension. White opaque 96-well plates (Fisher no. 08-771-26, Pittsburgh, PA, USA) prespotted with 1.25 pM of siRNA directed against cyclophilin B or a non-targeting control pool (Dharmacon RTF plates) were rehydrated with 25 ml of the dilutions of each transfection reagent in DCCR and allowed to sit at room temperature for 30 min. Cells were taken up with trypsin and counted using a hemocytometer. A suspension of 10 000 and 20 000 cells/100 ml was made using antibiotic-free complete media. A hundred microliters of this suspension was dispensed into each well on the siRNA plate. Cells were cultured for 48 h and then viability read using Cell Titer Glo (Promega, Madison, WI, USA) according to the manufacturers' instructions in duplicate. RNA was extracted from the wells containing siRNA targeting Cyclophilin B and non-targeting controls and reverse transcription performed per the manufacturers' protocol using the Ambion Cells-to-CT kit (Life Technologies), including an in-solution DNAse I digestion step. Knockdown was measured using Q-RT-PCR. Transfection conditions were chosen that resulted in 480% viability relative to untreated control and 450% knockdown of the target gene. Cell lines that had no such conditions identified (NB-1643) were deemed untransfectable in this system and omitted from further screening.
Primary siRNA screening. Duplicate pre-spotted 96-well plates containing 6.25 pM of siRNA targeting the deubiquiting enzymes (Dharmacon RTF ON-Target Plus library) were rehydrated with 25 ml of DharmaFect Cell Culture Reagent containing 0.075 ml DharmaFect 1 per well. After a 30 min incubation, 10 000 cells in 100 ml antibiotic-free otherwise complete RPMI was added to each well. After 24 h of incubation in standard conditions, 5 ml of antibiotic-free RPMI with or without ABT-737 at a concentration to give a final ABT-737 concentration of 200 nM was added to each well. Plates were incubated for an additional 48 h, and then ATP content was measured using Cell Titer Glo (Promega) per the manufacturers' instructions. ATP content in each well was calculated by normalizing the luminesce reading to a standard dilution of ATP (arbitrary units). Z-scores were calculated for each well by subtracting the measured ATP content from the mean ATP content for all experimental wells for the cell line and dividing by the S.D. of the ATP content for all experimental wells. Hits were defined as having a Z-score o À 1.5 and a ratio of (ATP: treated with ABT-737)/(ATP: treated with vehicle) o0.80. Figure 7 Spliceosome activities and Mcl1 regulation summary. The U1 spliceosome subunit is recruited to the 5 0 splice donor site at introns to form complex E. The U2 subunit (including SF3B) is subsequently recruited to form complex A, followed by recruitment of the U5-U4/U6 subunits (that includes Prpf8, Ubl5 and Sart1) generating complex B. The first transesterification reaction then occurs generating a lariat and releasing the U1 and U4 subunits. The second transesterification reaction occurs generating the mature mRNA by ligating the adjacent exons and releasing the remaining spliceosome subunits for recycling and the excised intron for degradation. SSA binds SF3B and delays progression from complex A to complex B, and SSA treatment or knockdown of the complex B subunits PRPF8, UBL5 or SART1 increase pro-apoptotic Mcl1-S splicing, decrease translation of antiapoptotic Mcl1-L protein and blocks the Mcl1 survival bias in Mcl1-dependent tumors, restoring sensitization to Bcl2 antagonists, such as ABT-737. BN82685 inhibits the second transesterification reaction and does not share this phenotype Cytotoxicity assays. For siRNA experiments, OnTarget Plus siRNA (Dharmacon) was rehydrated with siRNA Resuspension Buffer (Dharmacon). The siRNA sequences used for rescue experiments were selected from the pool of four as the siRNA having the greatest sensitization to ABT-737. The following siRNA were used: PSMD14 5 0 -GGCAUUAAUUCAUGGACUA-3 0 , PRPF8 5 0 -GCA GAUGGAUUGCAGUAUA-3 0 and UBL5 5 0 -GACCUUAAGAAGCUGAUUG-3 0 . For all other experiments, the pool of four siRNA targeting each gene was used and compared with ON-TARGETplus Non-targeting Control Pool (Dharmacon), a pool of four scrambled siRNA that do not target any human mRNA (siSham). In all, 6.25 pM of siRNA and 0.075 ml DharmaFect 1 were combined in 25 ml of DharmaFect Cell Culture Reagent per well. After 30-min incubation, 10 000 cells in 100 ml of antibiotic-free complete media was added to each well. After a 24-h incubation, ABT-737 was added in 5 ml of antibiotic-free complete medium. Fortyeight hours later, ATP content was measured using Cell Titer Glo (Promega) per the manufacturer's instructions. For experiments using chemical spliceosome inhibitors, cells were plated at the above densities and allowed to settle overnight. Cells were treated with SSA for 24 h (a kind gift of Minoru Yoshida, Riken Institute, Wako, Japan), Sudemycin C1 or E for 48 h (kind gifts of Thomas Webb, St. Jude Children's Research Center, Memphis, TN, USA), Meayamycin for 48 h (a kind gift of Kazunori Koide, University of Pittsburgh, Pittsburgh, PA, USA) or vehicle control and ABT-737 at the reported concentration and then ATP content was measured as above.
Intron
QPCR. Cells transfected as for cytotoxicity assays were cultured for 48 h. RNA was extracted from the wells containing siRNA targeting Cyclophilin B and nontargeting controls and reverse transcription performed per the manufacturers' protocol using the Ambion Cells-to-CT kit for siRNA knockdown in 96-well plates, including an in-solution DNAse I digestion step. For splicing interrogation, RNA from cells transfected in six-well plates was collected per the manufacturer's protocol using Qiagen's RNeasy kit (Qiagen, Venlo, Netherlands), including an oncolumn DNAse digestion step. cDNA was made using the SuperScript III FirstStrand Synthesis SuperMix per the manufacturor's protocol with 1 mg of RNA and then diluted 1 : 10 before PCR. Q-RT-PCR was performed on an Applied Biosystems 7900-HT instrument, using primer probes for Mcl1, UBL5, PSMD14, PRPF8, SART1, GapDH, HPRT, and the TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA). Relative mRNA was quantified using standard curves constructed from fetal brain RNA and normalized to total cellular mRNA content using HPRT as a neural housekeeping gene.
RT-PCR.
For siRNA experiments, cells transfected as for cytotoxicity assays were cultured for 48 h. For chemical spliceosome inhibitor experiments, cells were plated, allowed to settle overnight and then treated with drug or vehicle control for 6 h. RNA from cells transfected in six-well plates was collected per the manufacturer's protocol using Qiagen's RNeasy kit, including an on-column DNAse digestion step. cDNA was made using the SuperScript III First-Strand Synthesis SuperMix (Invitrogen, Grand Island, NY, USA) per the manufacturer's protocol with 1 mg of RNA and then diluted 1 : 10 before PCR. PCR using primers spanning splice junctions (Supplementary Table S2 ) was performed using GoTaq Green (Promega) per the manufacturer's protocol for 40 cycles with a 60 1C annealing temperature and 1 : 30 extension time. DNA from all reported splice variants was extracted using Qiagen's QIAquick PCR Purification Kit, and sequence was confirmed.
Immunoblots. Cells were harvested with Versene (8 g/l NaCl, 0.2 g/l KCl, 1.15 g/l Na2PO4, 0.2 g/l EDTA, 0.1 g/l Phenol red, pH 7.34), washed in ice-cold PBS and lysed on ice in a RIPA buffer with fresh protease inhibitors (Roche Complete, Roche Applied Science, Basel, Switzerland) and Phosphatase inhibitors (PhosSTOP, Roche Applied Science). Protein (25 mg) was electrophoresed through a 4-12% Bis-Tris gel, blotted to a PVDF membrane (iBLOT, Invitrogen) and immunoblotted using antibodies to: b-tubulin (Sigma T8328, Sigma-Aldrich, St. Louis, MO, USA), Mcl1 (Santa Cruz SC-819, Santa Cruz Biotechnology, Dallas, TX, USA), PSMD14 (Sigma HPA002114, Sigma-Aldrich), PRPF8 (Abcam ab79237, Cambridge, MA, USA), and SART1 (Abcam ab88583). Rabbit anti-Hub1(UBL5) antibody was a kind gift of Dr. Hideki Yashiroda (University of Tokyo, Tokyo, Japan). Blots were scanned, and densitometry was performed by the UN-SCAN-IT 6.1 software (Silk Scientific Inc, Orem, UT, USA).
Morpholino oligonucleotide transfection. IMR5 (400 000 cells/ml) and NLF (200 000 cells/ml) cells were plated in 96-well plates (cytotoxicity assays) and six-well plates (RT-PCR). Twenty-four hours after plating, the media was replaced with fresh RPMI containing 0.6% EndoPorter (GeneTools, Philomath, OR, USA) and the listed concentration of each morpholino oligonucleotide targeting the Mcl1 exon 2 splice acceptor site (5 0 -CGAAGCATGCCTGAGAAAGAAAAGC-3 0 ) and splice donor site (5 0 -AAGGCAAACTTACCCAGCCTCTTTG-3 0 ) or a scramble control. ABT-737 was added for cytotoxicity assays 24 h after morpholino treatment. Seventy-two hours after morpholino treatment, cytotoxicity was measured, and RNA was collected as above.
Protein half-life. IMR5 and NLF (200 000 cells/ml) cells were plated in 6-cm plates and reverse transfected with siRNA targeting PSMD14, PRPF8, UBL5 or Sham as for cytotoxicity assays. Forty-eight hours after plating, the media was replaced with fresh RPMI containing 50 mg/ml cyclohexamide (Sigma-Aldrich). After the indicated incubation period, cells were harvested for immunoblots as above. 0 -GCTGGTTTGGCATATCTAATAAGATAGCCTTACTGTAAGACCCAGCTTTCTTG TACAAAG-3 0 and its reverse compliment. To express tagged Mcl1-S, the TAA stop codon of the above primer was replaced with TTA. These plasmids were cloned into the pTRex-DEST30 vector using Invitrogen LR Clonase per the manufacturer's instructions. The insert of each vector was fully sequence confirmed. For transfection, cells were plated to be 60-80% confluent after settling overnight in a six-well plate in complete antibiotic-free media. A total of 10 ml of Lipofectamine 2000 (Invitrogen) and 4 mg of plasmid were combined in 500 ml serum-free RPMI and allowed to sit for 30 min before addition to each well. After 16-h incubation, cells were replated into a T75 flask in antibiotic-free media. Forty-eight hours after transfection, cells were selected with and maintained in RPMI supplemented with Geneticin (Invitrogen) 250 mg/ml. For tetracycline-regulated experiments, IMR5 and NLF were first transfected as above with pcDNA-TR6 (Invitrogen). Cells were selected with Blasticidin (Invitrogen) 4 mg/ml and dilutionally subcloned. Subclones were screened for expression of the TR element by western blotting using a MoBiTec antibody. Cells were then transfected with the DEST30 vector as above and selected and maintained in RPMI supplemented with Blasticidin 2 mg/ml and Geneticin 250 mg/ml.
Gene expression correlates. Publicly available NB data sets were analyzed using the R2 Microarray Analysis and Visualization platform (r2.amc.nl). The Kocak data set (GEO GSE45547) includes expression data from 649 diverse NBs with age, stage and MYCN status known, utilizing a single-color 44K oligonucleotide microarray. 60 The Versteeg data set (GEO GSE16476) includes expression data from 88 NBs annotated additionally with survival outcome, utilizing the Affymetrix U133 þ 2 genechip (Affymetrix, Santa Clara, CA, USA).
Statistical analyses. Data are presented as mean ± S.E.M. For primary screening, Z-scores were calculated as the measured ATP content minus the mean ATP content for all experimental wells divided by the S.D. For cytotoxicity curves, the viability was modeled as function of concentration and experiment group using a log-logistic regression model. All models were fitted using the 'drm' function in the 'drc' add-on package in R (R Core Team, 2013). We compared the residual sums of squares from the reduced model, which does not include experiment group variable with that from the full model, including experiment group variable to test the hypothesis of no difference between two experiments using the F-test. mRNA expression was analyzed with the two-tailed Student's t-test using GraphPad Prism 5.0 for Macintosh (GraphPad Software, San Diego, CA, USA). Differences were considered significant at Po0.05. All data shown represent at least two independent replicates.
